Search

Your search keyword '"Vario, Alessandro"' showing total 13 results
Start Over Author "Vario, Alessandro"
13 results on '"Vario, Alessandro"'

1. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

Author

Degasperi, Elisabetta, Spinetti, Angiola, Lombardi, Andrea, Landonio, Simona, Rossi, Maria Cristina, Pasulo, Luisa, Pozzoni, Pietro, Giorgini, Alessia, Fabris, Paolo, Romano, Antonietta, Lomonaco, Lorenzo, Puoti, Massimo, Vinci, Maria, Gatti, Federico, Carolo, Giada, Zoncada, Alessia, Bonfanti, Paolo, Russo, Francesco Paolo, Aghemo, Alessio, Soria, Alessandro, Centenaro, Riccardo, Maggiolo, Franco, Rovere, Pierangelo, Pasin, Francesca, Paon, Veronica, Faggiano, Giovanni, Vario, Alessandro, Grossi, Glenda, Soffredini, Roberta, Carriero, Canio, Paolucci, Stefania, Noventa, Franco, Alberti, Alfredo, Lampertico, Pietro, and Fagiuoli, Stefano

Published
2019
Full Text
View/download PDF

4. Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy

Author

Fabris, Paolo, primary, Noventa, Franco, additional, Fagiuoli, Stefano, additional, Farina, Francesca, additional, Carolo, Giada, additional, Carlotto, Antonio, additional, Rovere, Pierangelo, additional, Cavinato, Silvia, additional, Romano, Antonietta, additional, Vario, Alessandro, additional, Franceschet, Irene, additional, Panese, sandro, additional, Bertin, Tosca, additional, Zappalà, Francesco, additional, Alberti, Alfredo, additional, Lobello, Salvatore, additional, Aghemo, Alessio, additional, Bruno, Raffaele, additional, Puoti, Massimo, additional, Rizzardini, Giuliano, additional, Spinelli, Ombretta, additional, Pigozzi, Marie Graciella, additional, Spinetti, Angiola, additional, Menzaghi, Barbara, additional, Pan, Angelo, additional, Bella, Daniele, additional, Re, Tiziana, additional, Borghi, Marta, additional, Lombardi, Andrea, additional, Viganò, Mauro, additional, Salpietro, Stefania, additional, Lleo, Ana, additional, and Del Punta, Veronica, additional

Published
2020
Full Text
View/download PDF

6. Efficacy and safety of DAA-based oral therapy i9n a large cohort of HCV patients treated in clinical practice in Italy and monitored by the NAVIGATORE web-platform

Author

Milan, Marta, Scotton, Piergiorgio, Cavallaro, Lucas G., Basso, Monica, Panese, Sandro, Tempesta, Diego, Piovesan, Sara, Cattelan, Anna Maria, Campagnolo, Davide, Burra, Patrizia, Russo, Francesco P., Carlotto, Antonio, Angeli, Paolo, Vario, Alessandro, Fabris, Paolo, Bertin, Tosca, Carrara, Maurizio, Chemello, Liliana, Rovere, Pierangelo, Capra, Franco, Carolo, Giada, Lobello, Salvatore, Adami, Silvia, Scroccaro, Giovanna, and Alberti, Alfredo

Subjects
DAAs oral therapy
Published
2016

12. FRI401 - Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy.

Author

Fabris, Paolo, Noventa, Franco, Fagiuoli, Stefano, Farina, Francesca, Carolo, Giada, Carlotto, Antonio, Rovere, Pierangelo, Cavinato, Silvia, Romano, Antonietta, Vario, Alessandro, Franceschet, Irene, Panese, sandro, Bertin, Tosca, Zappalà, Francesco, Alberti, Alfredo, Lobello, Salvatore, Aghemo, Alessio, Bruno, Raffaele, Puoti, Massimo, and Rizzardini, Giuliano

Subjects
*INFECTION, *VIRAL hepatitis, *HEPATITIS B
Published
2020
Full Text
View/download PDF

13. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

Author

Sebastiani G, Vario A, Guido M, and Alberti A

Subjects
Adult, Alanine Transaminase blood, Algorithms, Area Under Curve, Aspartate Aminotransferases blood, Biopsy, Female, Humans, Male, Middle Aged, Hepatitis B, Chronic complications, Liver pathology, Liver Cirrhosis diagnosis
Abstract

Aim: To assess the performance of several non-invasive markers and of our recently proposed stepwise combination algorithms to diagnose significant fibrosis (F > or = 2 by METAVIR) and cirrhosis (F4 by METAVIR) in chronic hepatitis B (CHB)., Methods: One hundred and ten consecutive patients (80 males, 30 females, mean age: 42.6 +/- 11.3) with CHB undergoing diagnostic liver biopsy were included. AST-to-Platelet ratio (APRI), Fornso index, AST-to-ALT Ratio, Goteborg University Cirrhosis Index (GUCI), Hui's model and Fibrotest were measured on the day of liver biopsy. The performance of these methods and of sequential algorithms combining Fibrotest, APRI and biopsy was defined by positive (PPV) and negative (NPV) predictive values, accuracy and area under the curve (AUC)., Results: PPV for significant fibrosis was excellent (100%) with Forns and high (> 92%) with APRI, GUCI, Fibrotest and Hui. However, significant fibrosis could not be excluded by any marker (NPV < 65%). Fibrotest had the best PPV and NPV for cirrhosis (87% and 90%, respectively). Fibrotest showed the best AUC for both significant fibrosis and cirrhosis (0.85 and 0.76, respectively). Stepwise combination algorithms of APRI, Fibrotest and biopsy showed excellent performance (0.96 AUC, 100% NPV) for significant fibrosis and 0.95 AUC, 98% NPV for cirrhosis, with 50%-80% reduced need for liver biopsy., Conclusion: In CHB sequential combination of APRI, Fibrotest and liver biopsy greatly improves the diagnostic performance of the single non-invasive markers. Need for liver biopsy is reduced by 50%-80% but cannot be completely avoided. Non-invasive markers and biopsy should be considered as agonists and not antagonists towards the common goal of estimating liver fibrosis.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results